| scholarly article | Q13442814 |
| P50 | author | Puthen Jithesh | Q42325135 |
| Heinz-Josef Lenz | Q89668545 | ||
| P2093 | author name string | Senji Shirasawa | |
| Patrick G Johnston | |||
| Takehiko Sasazuki | |||
| Daniel B Longley | |||
| Mark Lawler | |||
| Murugan Kalimutho | |||
| Paolo Michieli | |||
| Sandra Van Schaeybroeck | |||
| Keara L Redmond | |||
| Wendy Allen | |||
| Cathy Fenning | |||
| Philip D Dunne | |||
| Jaine Blayney | |||
| Robbie Carson | |||
| P433 | issue | 6 | |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 1940-1955 | |
| P577 | publication date | 2014-06-12 | |
| P1433 | published in | Cell Reports | Q5058165 |
| P1476 | title | ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. | |
| P478 | volume | 7 |
| Q37052477 | ADAM Proteases and Gastrointestinal Function |
| Q94503511 | ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance |
| Q64254582 | Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8 T-cells infiltration in triple-negative breast cancer |
| Q58779939 | CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer |
| Q89966984 | Caveolin-1 Promotes Chemoresistance of Gastric Cancer Cells to Cisplatin by Activating WNT/β-Catenin Pathway |
| Q90702159 | Current advances of targeting HGF/c-Met pathway in gastric cancer |
| Q36893736 | Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program |
| Q61796614 | Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer |
| Q37457602 | Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models |
| Q38973740 | Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. |
| Q36411034 | EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer |
| Q91523126 | Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells |
| Q94673409 | GPR50 Promotes Hepatocellular Carcinoma Progression via the Notch Signaling Pathway through Direct Interaction with ADAM17 |
| Q91239717 | Gamma-secretase-dependent signaling of receptor tyrosine kinases |
| Q38894659 | HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL |
| Q61445424 | JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer |
| Q91361655 | Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours |
| Q51091805 | Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer |
| Q26747329 | Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer |
| Q38794338 | Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications |
| Q55256271 | PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer. |
| Q36113481 | Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases |
| Q101120951 | RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer |
| Q35987390 | Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells |
| Q46450905 | Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. |
| Q37544392 | Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells |
| Q61445004 | Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway |
| Q61802776 | Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway |
| Q93101595 | STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway |
| Q38611166 | Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. |
| Q38390840 | Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. |
| Q38485889 | Targeting JAK kinase in solid tumors: emerging opportunities and challenges |
| Q38856729 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges |
| Q37554536 | The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells |
| Q90091971 | The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer |
| Q52684450 | The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer |
| Q37694731 | Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer |
| Q58577633 | USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells |
Search more.